Skip to content

Study · Animal study (in vivo) · mouse · 2022

8 results

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.

Yang Y, Peng Z, Flores ER, Kleinerman ES

Cancers2 Sept 2022Cited by 10 (Europe PMC)

PMID36077845 (opens in a new tab)PMCIDPMC9454976 (opens in a new tab)DOI10.3390/cancers14174310 (opens in a new tab)PepBankPUB-36077845
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Despite aggressive combination chemotherapy and surgery, outcomes for patients with osteosarcoma have remained stagnant for more than 25 years, and numerous clinical trials have identified no new therapies. p53 deletion or mutation is found in more than 80% of osteosarcoma tumors. In p53-deficient cancers with structurally altered p63 and p73, interfering with tumor cell metabolism using Pramlintide (an FDA-approved drug for type 2 diabetes) results in tumor regression. Pramlintide response is mediated through upregulation of islet amyloid polypeptide (IAPP). Here, we showed that osteosarcoma cells have altered p63, p73, and p53, and decreased IAPP expression but have the two main IAPP receptors, CalcR and RAMP3, which inhibit glycolysis and induce apoptosis. We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro. In contrast, Pramlintide had no effect in osteosarcoma cells with low glycolytic activity. Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression. Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α. These data suggest that in osteosarcoma cells with altered p53, p63, and p73 and a high glycolytic function, Pramlintide therapy can modulate metabolic programming and inhibit tumor growth.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse osteosarcoma model, intratumoral pramlintide induced tumor regression.

    In plain wordsIn mice with osteosarcoma, pramlintide injected into tumors caused tumor regression.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseTumor regression
    Study

    mousen: not reported in source

    Subcutaneous osteosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoral injectionAs given in this study (mouse).

    Source sentences

    Summary
    Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mouse osteosarcoma tumor sections, pramlintide treatment increased apoptosis.

    In plain wordsIn mice with osteosarcoma, tumor sections showed more programmed cell death after pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseTumor apoptosis
    Study

    mousen: not reported in source

    Subcutaneous osteosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoral injectionAs given in this study (mouse).

    Source sentences

    Summary
    Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α.
    1 context sentence
    Summary · context
    Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mouse osteosarcoma tumor sections, pramlintide treatment decreased Ki-67.

    In plain wordsIn mice with osteosarcoma, tumor sections showed less Ki-67 after pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseKi-67
    Study

    mousen: not reported in source

    Subcutaneous osteosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoral injectionAs given in this study (mouse).

    Source sentences

    Summary
    Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α.
    1 context sentence
    Summary · context
    Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mouse osteosarcoma tumor sections, pramlintide treatment decreased HIF-1α.

    In plain wordsIn mice with osteosarcoma, tumor sections showed less HIF-1α after pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseHIF-1α
    Study

    mousen: not reported in source

    Subcutaneous osteosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoral injectionAs given in this study (mouse).

    Source sentences

    Summary
    Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α.
    1 context sentence
    Summary · context
    Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression.
  5. 05LabIn vitro (cells)Mechanism

    In osteosarcoma cells with high or intermediate glycolytic activity, pramlintide decreased glycolysis.

    In plain wordsIn cells with high or intermediate glycolytic activity, pramlintide reduced glycolysis.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseGlycolysis
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro.
  6. 06LabIn vitro (cells)Efficacy outcome

    In osteosarcoma cells with high or intermediate glycolytic activity, pramlintide decreased proliferation.

    In plain wordsIn cells with high or intermediate glycolytic activity, pramlintide reduced cell multiplication.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseProliferation
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro.
  7. 07LabIn vitro (cells)Mechanism

    In osteosarcoma cells with high or intermediate glycolytic activity, pramlintide increased apoptosis.

    In plain wordsIn cells with high or intermediate glycolytic activity, pramlintide increased programmed cell death.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseApoptosis
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro.
  8. 08LabIn vitro (cells)Efficacy outcome

    In osteosarcoma cells with low glycolytic activity, pramlintide had no effect.

    In plain wordsIn cells with low glycolytic activity, pramlintide had no effect.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeCell response at low glycolytic activity
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, Pramlintide had no effect in osteosarcoma cells with low glycolytic activity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.